

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5537531

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JOHN LI	04/12/2019
XIAOLEI ZHUANG	04/12/2019
RECEIVING PARTY DATA	
Name:	SALUBRIS BIOTHERAPEUTICS, INC.
Street Address:	45 WEST WATKINS MILL ROAD
Internal Address:	SUITE 3
City:	GAITHERSBURG
State/Country:	MARYLAND
Postal Code:	20878
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16381206
PCT Number:	US2019026889
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6179372340
Email:	lromano@cooley.com
Correspondent Name:	MATTHEW PAVAO
Address Line 1:	COOLEY LLP
Address Line 2:	1299 PENNSYLVANIA AVENUE NW
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	SBTI-001/001US - SALUBRIS
NAME OF SUBMITTER:	MATTHEW PAVAO
SIGNATURE:	/ Matthew Pavao /
DATE SIGNED:	05/23/2019
Total Attachments: 6	
source=SBTI-001001US - Assignment - Salubris#page1.tif	
source=SBTI-001001US - Assignment - Salubris#page2.tif	

source=SBTI-001001US - Assignment - Salubris#page3.tif

source=SBTI-001001US - Assignment - Salubris#page4.tif

source=SBTI-001001US - Assignment - Salubris#page5.tif

source=SBTI-001001US - Assignment - Salubris#page6.tif

ASSIGNMENT

JOHN LI, and XIAOLEI ZHUANG (each referred to as "Assignor") have made an inventions (the "Inventions") set forth in an application for patent entitled **HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF**, and which is a:

- (1) provisional application
 - (a) to be filed herewith; or
 - (b) bearing Application No. , and filed on ;
- (2) non-provisional application
 - (a) to be filed herewith; or
 - (b) bearing Application No. 16/381,206, and filed on April 11, 2019; and
- (3) PCT application
 - (a) bearing Application No. PCT/US2019/026889, and filed on April 11, 2019.

WHEREAS, Salubris Biotherapeutics, Inc., a having its principal place of business at **45 West Watkins Mill Road, Suite E, Gaithersburg, MD 20878**, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

(a) the Invention(s);

(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with

any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.


The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 04/12/2019 By: 
JOHN LI

Witness Signature:  Date: APR 12, 2019

Print Witness Name: GENG YU

Witness Signature:  Date: APR 12, 2019

Print Witness Name: BENJAMIN BEZALEH

Date: 04/12/2019 By: Xiaolei Zhuang
XIAOLEI ZHUANG

Witness Signature: [Signature] Date: APR 12, 2019


Print Witness Name: GENG YU

Witness Signature: [Signature] Date: APR 12, 2019

Print Witness Name: Binyan BEZABSH

For and on behalf of ASSIGNEE:

Date: 04/12/2019

By: 

Name: John Li


Title: CEO

Company: Salubris Biotherapeutics, Inc.

Witness Signature: 

Date: APR 12 2019

Print Witness Name: GENG YU

Witness Signature: 

Date: APR 12, 2019

Print Witness Name: BENJAMIN BEZAKEN